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Structure-based reverse vaccinology (RV) (1) attempts to develop an HIV-1 vaccine by determining 
the 3-D structure of complexes of HIV-1 Env epitopes bound to broadly neutralizing monoclonal 
antibodies (bnMabs) (2). For more than 10  years, hundreds of investigators have tried, without 
success, to transform Env epitopes of known structure into effective vaccine immunogens, because 
they thought that epitopes that bind to affinity-matured bnMabs would also be able to induce similar 
antibodies when used as immunogens (3).
Using the convergence argument (4), I suggested that all these independently obtained negative 
results justified the conclusion that RV was unlikely to lead to a successful vaccine because it is based 
on invalid reductionist thinking (5). King (6) disagreed with this conclusion because it was based 
on inductive reasoning (i.e., generalizing from a limited body of evidence), and there was therefore 
no “proof ” that the conclusion was correct (7). Indeed, experimental science never leads to absolute 
certainty, since certainties are only achieved by logical, deductive reasoning and are not derived 
from empirical experimentation. When Einstein declared “It makes no sense to do the same thing 
over and over again and expect a different result,” he did not contest that scientific conclusions are 
always reached by inductive inferences that may have only a reasonable probability of being correct.
My convergence argument that RV is inappropriate for developing an HIV vaccine, however, 
was only a back-up argument (5), since the actual reason why RV failed is that it did not have a 
sound theoretical basis corresponding to our current knowledge of immunological specificity and 
anti-HIV immune responses. For instance, RV does not take into account that the immune system 
is degenerate (3, 8) and that antibodies and paratopes are never monospecific for a single epitope 
but are always polyspecific (9) or even heterospecific (10) for a large number of epitopes. This means 
that a single antibody is always able to bind several epitopes, besides the one observed by X-ray 
crystallography of one paratope–epitope complex. Thus, there is no reason to believe that this epitope 
of known structure is necessarily the one that induced the antibody and could be expected to elicit 
bnAbs when used as vaccine immunogen.
Another theoretical misunderstanding by many proponents of RV is that they believe that when 
they improve the antigenic reactivity of one Env epitope with respect to a single bnMab, using 
molecular engineering, this amounts to “designing” a superior vaccine immunogen capable of elicit-
ing protective antibodies (11). In so doing, they confuse antigenicity, which is a chemical property 
that allows a molecule to bind to an antibody, with immunogenicity, which is a biological property 
involving an appropriate immune system. This is typical of reductionist thinking, which assumes that 
biology can be reduced to chemistry and that an antigen is necessarily able to elicit the antibodies that 
it can react with. In fact, many factors that determine which antibodies will be produced are external 
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to epitope–paratope recognition and originate in the immunized 
host. RV is also ineffective in the case of HIV, because neutralizing 
anti-HIV Abs are only obtained after a lengthy process of Ab affin-
ity maturation, which is usually not the case for immune responses 
to other viruses. As a result, RV is not applicable to the epitopes 
of known structure that are recognized only by affinity-matured 
antibodies. Current attempts to develop vaccine immunogens 
from Env epitopes that do not bind germline B cell receptors or 
maturation intermediates present in naive individuals actually 
depart from the original RV strategy, which does not require the 
unraveling of antibody maturation pathways (11).
Another reductionist limitation of RV is that it makes use only 
of epitopes recognized by a limited number of bnMabs, thereby 
neglecting the fact that the entire surface of a protein contains 
a very large number of overlapping epitopes and potentially 
immunogenic regions (12). However, it is well-known that effec-
tive vaccine-induced antibody responses are always polyclonal 
and recognize a wide variety of epitopes (13).
King (6) also pointed out that HIV vaccine development and 
related efficacy trials in humans present numerous ethical con-
straints that are particularly challenging. He suggested that it may 
be unethical to pursue attempts to develop an HIV-1 vaccine by 
RV, if scarce resources could be used more effectively to combat 
the AIDS epidemic and its huge societal problems by other means. 
Such a conclusion is reinforced by the theoretical shortcomings of 
RV outlined above, which suggest that other vaccine approaches 
should rather be investigated and funded (14).
It could also be argued that the unwillingness of regulatory 
authorities to allow small-scale human vaccine trials, unless posi-
tive results have been obtained earlier with non-human primates 
(NHPs), may also be ethically questionable. It is widely accepted 
today that a vaccine response in NHPs (whether positive or nega-
tive) is not at all predictive of what is likely to happen in humans 
(15, 16). For instance, this means that a vaccine that shows no 
efficacy in NHPs may never be tested in humans, and thus that its 
possible efficacy would not be discovered because of ethical con-
siderations. For instance, it is obvious today that the thalidomide 
disaster could not have been avoided if pregnant NHPs had first 
been tested in toxicity trials, since the drug is only teratogenic 
in humans (17). It should in fact be accepted that the only reli-
able model system for a human vaccine are human subjects (18, 
19). Small-scale human trials (20, 21), using, for instance, HIV-
infected individuals with temporarily interrupted ART, may be 
one approach that could be used to evaluate potential therapeutic 
HIV vaccines.
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